Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

ADAR1 Capital Management challenges Keros Therapeutics on capital allocation and board decisions. Read more here.

Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We ...

Keros Therapeutics shareholder ADAR1 Capital Management said it plans to withhold votes for board members Mary Ann Gray and Alpna Seth.

Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing ...

LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat ...

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting "FOR" the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 ...

LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros” or the "Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Keros Therapeutics, Inc. issued a statement addressing misleading claims made by ADAR1 Capital Management ahead of its upcoming 2025 Annual Meeting of Stockholders on June 4, 2025. Keros' Board is ...

Keros Therapeutics (KROS) delivered earnings and revenue surprises of 36,300% and 149.64%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?